84例弥漫大B细胞淋巴瘤组织中MYD88基因突变及其临床意义  

Gene mutation and clinical significance of MYD88 in 84 cases of diffuse large B-cell lymphoma

作　　者：胡飘飘 杜华 李时荣 翁立新 海玲 乌云嘎 徐晓艳 HU Piao-piao;DU Hua;LI Shi-rong;WENG Li-xin;HAI Ling;WU Yun-ga;XU Xiao-yan(Department of Pathology,College of Basic Medical Sciences,Inner Mongolia Medical University,Huhhot 010059,China)

机构地区：[1]内蒙古医科大学基础医学院病理学教研室,呼和浩特010059

出　　处：《临床与实验病理学杂志》2022年第12期1452-1457,共6页Chinese Journal of Clinical and Experimental Pathology

摘　　要：目的探讨人弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)中MYD88基因突变及其与临床病理特征、预后的关系。方法采用Sanger测序法检测DLBCL中MYD88 L265P基因突变情况;采用免疫组化法检测MYD88、p53、c-MYC、BCL-2、BCL-6、Ki-67、CD5的表达;分析MYD88 L265P基因突变和蛋白表达与各临床病理特征及预后的相关性。结果DLBCL中MYD88 L265P基因突变率为26.19%(22/84),与Hans分型、MYD88、p53、BCL-2蛋白表达密切相关(P<0.05),且与MYD88蛋白表达呈正相关(P<0.006);MYD88蛋白阳性率为39.29%(33/84),与Hans分型、MYD88 L265P基因突变、BCL-2蛋白表达密切相关(P<0.05);DLBCL患者生存率与患者年龄、血清LDH水平、MYD88 L265P基因突变及MYD88、c-MYC、BCL-2蛋白表达有关(P<0.05);Logistic回归分析显示:患者年龄、Hans分型、MYD88 L265P基因突变及MYD88、BCL-2蛋白表达与DLBCL患者的预后相关(P<0.05)。结论MYD88 L265P突变与其蛋白表达呈正相关,其与患者生存率和预后显著相关,可作为DLBCL治疗和预后的有效参考指标。Purpose To investigate the correlation between MYD88 gene mutation and clinicopathological features and prognosis in human diffuse large B-cell lymphoma(DLBCL).Methods The mutation of MYD88 L265 P gene was detected by Sanger sequencing method,Immunohistochemical staining was used to detect the expression of MYD88,p53,c-MYC,BCL-2,BCL-6,Ki-67 and CD5 proteins.The correlation between MYD88 L265 P gene mutation,protein expression and various clinicopathological parameters and prognosis was analyzed by statistical method.Results The mutation rate of MYD88 L265 P gene was 26.19%(22/84),which was closely related to the protein expression of MYD88,p53,BCL-2 and Hans’typing(P<0.05).The positive rate of MYD88 protein expression was 39.29%(33/84),which was closely related to Hans’typing,MYD88 L265 P gene mutation and BCL-2 protein expression.The survival rate of patients with DLBCL was related to age,serum LDH level,MYD88 L265 P gene mutation and protein expression of MYD88,c-MYC and BCL-2(P<0.05).Age,Hans’classification,MYD88 L265 P mutation,protein expression of MYD88 and BCL-2 were associated with the prognosis of DLBCL patients(P<0.05).Conclusion MyD88 L265 P mutation is positively correlated with its protein expression,which is significantly correlated with the survival rate and prognosis of patients,and can be used as an effective reference indicator for DLBCL treatment and prognosis.

关 键 词：弥漫大B细胞淋巴瘤 MYD88 L265P 基因突变 预后 

分 类 号：R733.4[医药卫生—肿瘤]